ZYBT vs DBVT vs ALKS vs ATXG

For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.

2% revenue growth year-over-year, versus -18. 9% for Addentax Group Corp. (ATXG). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 6% for Addentax Group Corp. (ATXG). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus ATXG's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Zhengye Biotechnology Holding Limited's 1. 75β — meaning ZYBT is approximately 75% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 103% for Addentax Group Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.

2% versus -18. 9% for Addentax Group Corp. (ATXG). On earnings-per-share growth, the picture is similar: Addentax Group Corp. grew EPS -19. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -121. 8% for Addentax Group Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -43. 5% for ATXG. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ZYBT (5.

3% yield) pays a dividend. DBVT, ALKS, ATXG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Both have compounded well over 10 years (ALKS: -12. 0%, ATXG: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and ATXG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ATXG is a small-cap quality compounder stock. ZYBT pays a dividend while DBVT, ALKS, ATXG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.